| P2093 | author name string | Nancy S Vetter | |
| | Valerie B Sampson | |
| | E A Kolb | |
| | Christopher C Mills | |
| P2860 | cites work | Mir-34: a new weapon against cancer? | Q38253374 |
| | Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma | Q38893024 |
| | Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression | Q38956681 |
| | The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53. | Q39042471 |
| | RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. | Q39197006 |
| | miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 |
| | p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. | Q39810065 |
| | Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples | Q39820788 |
| | Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells | Q40175774 |
| | MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms | Q42945633 |
| | Development of ribozymes that target stathmin, a major regulator of the mitotic spindle | Q45875778 |
| | Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer | Q46516617 |
| | Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. | Q46878496 |
| | Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest | Q48078984 |
| | The pediatric preclinical testing program: description of models and early testing results. | Q48387109 |
| | Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. | Q51750364 |
| | MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. | Q54334886 |
| | In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. | Q54369636 |
| | Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. | Q54416532 |
| | Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 | Q57272633 |
| | Circulating miRNA Signatures: Promising Prognostic Tools for Cancer | Q57693485 |
| | Human and rat osteoblast-like cells express stathmin, a growth-regulatory protein | Q24311658 |
| | Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration | Q24617268 |
| | Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma | Q24801656 |
| | MicroRNAs and Potential Targets in Osteosarcoma: Review | Q26784033 |
| | The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer | Q26799353 |
| | MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer | Q26801108 |
| | miR-34: from bench to bedside | Q26822928 |
| | MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 |
| | MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells | Q28287986 |
| | The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network | Q28567400 |
| | Cloning and characterization of the 5'-flanking region of the rat neuron-specific Class III beta-tubulin gene | Q28580697 |
| | Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 |
| | Stathmin regulates centrosomal nucleation of microtubules and tubulin dimer/polymer partitioning. | Q30489220 |
| | Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel | Q31152523 |
| | Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program | Q33406382 |
| | Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells | Q33723723 |
| | FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin | Q33991617 |
| | MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo | Q34211970 |
| | Do beta-tubulin mutations have a role in resistance to chemotherapy? | Q34303431 |
| | Osteosarcoma: a review of diagnosis, management, and treatment strategies. | Q34626942 |
| | Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma | Q35137803 |
| | MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1. | Q35201698 |
| | P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane | Q35376227 |
| | Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression | Q35991706 |
| | MicroRNAs and other non-coding RNAs as targets for anticancer drug development | Q35994443 |
| | Sp transcription factor family and its role in cancer | Q36279169 |
| | Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer | Q36756699 |
| | Osteosarcoma: the COSS experience | Q37705062 |
| | 1p36 tumor suppression--a matter of dosage? | Q38061568 |
| P433 | issue | 7 | |
| P304 | page(s) | 953-964 | |
| P577 | publication date | 2017-03-08 | |
| P1433 | published in | Molecular Cancer Research | Q2751014 |
| P1476 | title | The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis. | |
| P478 | volume | 15 | |